Pfizer Inc. 

(Public, NYSE:PFE)   Watch this stock   
Find more results forNYSE: PFE
Oct 20, 2009
Q3 2009 Earnings Conference Call
Oct 20, 2009
Q3 2009 Earnings Release
Sep 15, 2009
Morgan Stanley Global Healthcare Conference - Webcast
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 24.77% 16.67%
Operating margin 34.17% 20.07%
EBITD margin - 29.01%
Return on average assets 8.23% 7.11%
Return on average equity 17.88% 13.11%
Employees 80,250 -

Address

235 East 42nd Street
New York, NY 10017
United States - Map
+1-212-7332323 (Phone)
+1-212-5737851 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
About Company - Wikipedia

Pfizer Inc. discussed on blogs

mcbrooklyn: The Brooklyn Portfolio: One Month Report - mcbrooklyn - mcbrooklyn - 4 hours ago
Stock Picks For Wednesday: Cell Therapeutics, Tellabs And American ... - Antonio Costa - Daily Markets - Nov 25, 2009
Ranking 300+ Large Cap Stocks by Earnings Growth Potential ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 24, 2009

Pfizer Inc. discussions

  View all discussions »

Description

Pfizer Inc. (Pfizer) is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. In June 2008, Pfizer completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals, Inc. through a merger of Pfizer's wholly owned subsidiary, Explorer Acquisition Corp., with and into Encysive. In June 2008, it also completed the acquisition of Serenex, Inc., a biotechnology company with a Heat Shock Protein 90 development portfolio. In July 2009, Pfizer bought back a 29.52% stake in its Indian arm, Pfizer Limited, increasing its stake to 70.75%.In October 2009, Pfizer Inc. acquired Wyeth.

Officers and directors

Jeffrey B. Kindler
Chairman of the Board, Chief Executive Officer
Portrait Age: 53
Bio & Compensation - Reuters
Frank A. D'Amelio
Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation - Reuters
Elizabeth Barrett
Regional President of U.S., Oncology Business Unit
Bio & Compensation - Reuters
Amy W. Schulman
Senior Vice President, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation - Reuters
Mary S. McLeod
Senior Vice President - Worldwide Human Resources
Age: 52
Bio & Compensation - Reuters
Ian C. Read
Senior Vice President and President - Worldwide Pharmaceutical Operations
Age: 55
Bio & Compensation - Reuters
Natale S. Ricciardi
Senior Vice President and President - Pfizer Global Manufacturing
Age: 60
Bio & Compensation - Reuters
Martin Mackay
Senior Vice President and President - Pfizer Global Research & Development
Age: 52
Bio & Compensation - Reuters
Sally Susman
Senior Vice President, Chief Communications Officer
Age: 47
Bio & Compensation - Reuters
William R. Ringo Jr.
Senior Vice President - Strategy and Business Development
Age: 63
Bio & Compensation - Reuters